Imagion Nanoparticle Manufacturing Update
Saying we are pleased with the progress would be an understatement,” said Bob Proulx, Executive Chairman of Imagion Biosystems. “We took great care in our preparations before commencing manufacturing and that has paid off. The first step of the production process is the trickiest, so completing this step on schedule is encouraging.”
$3.3 Million raised in late November 2019, FDA fast track designation given, toxicology and pre-human results excellent, floated at 20 cents June 2017, Top 20 hold around 75%, only 500 million shares on issue, received $2 million research grant last year, Scientific Advisory Board excellent.
This is an interesting company. They are proposing to develop a new biomedical imaging technology that uses magnetic nanoparticles that are specifically targeted to a cancer type.
There are two parts to the strategy. The first which they have delivered on to some extent is the synthesis of iron oxide particles coated with a stealth polymer coating and conjugated with antibodies that target breast cancer. The in vitro cell studies for this in breast cancer cell lines looked convincing and the toxicology studies showed low toxicity. I haven't seen any animal work, but they seem to be looking to do some first in human studies this year. Still a long way to go here but a good start. They have sold $300k of the nanoparticles to an Israeli company.
The second aspect is developing the instrumentation that can detect this particles for clinical use. They have partners for instrument development, but the progress and role of each partner is not clear. It is also not clear how far off the clinical instruments are from even getting a prototype. There is a lot of work to do on the instrument side. In theory the instrumentation they are developing is more sensitive, i.e. can detect smaller tumours, but it is not clear what sort of read out/image would be obtained.
They can do the first in human studies using MRI systems, but these particles are not ideal contrast agents for use in MRI. The physics means that particles make images duller (negative contrast) rather than brighter (positive contrast). Positive contrast is easier to pick up. In saying that they do have a partnership with Siemens a major MRI system supplier.
All in all there is potential here, but still lots of work to do to show real clinical efficacy. We are probably talking at least 10 years for their primary aim of developing clinical magnetic relaxometry scanners.
Imagion announced the publication of a study looking at the use of it's nanoparticles as part of a novel HIV therapy.
See the announcement for a link to the publication. It's very difficult to understand - I'm a vet and even I could hardly undertand the title, let alone the rest of the paper!
But again, great to see the potential for further new revenue streams to help fund the R&D of Imagion's core technology.
Imagion announces plan to undertake first clinical study in Australia Live Webcast Scheduled
IBX announced today that they have entered into a calloaboration agreement with Siemens to further explore the use of Imagion's MagSense nanoparticles as an MRI contrast agent.
Very exciting news and great to have attracted the interest of a huge healthcare company.
Another revenue stream opportunity to help fund the R&D and regulatory hurdles for Imagion's own imaging technology.
Stock up 11% today. Third bar reversal, so something could be around the corner.
Hasn't been much news since the nanoparticle sale announcement in November 2019, yet the share is looking very strong. $15 million MC with $3.4 million in the bank.